Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
STIM submitted a Form 144 notice to sell 16,005 shares of Common Stock tied to Restricted Stock Vesting with an effective date of 12/31/2025.
The filing also discloses recent dispositions by William A. Macan: 3,485 shares on 02/10/2026, 14,120 shares on 02/12/2026, 3,427 shares on 02/26/2026, and 609 shares on 03/04/2026.
STIM submitted a Form 144 notice reporting a proposed sale of Common stock associated with a restricted stock vesting event. The filing lists 46,289 shares tied to 03/18/2026 as the securities to be sold. The filing also discloses recent dispositions by Keith Sullivan of 40,976, 33,847, and 8,452 shares on 02/10/2026, 02/12/2026, and 02/26/2026, respectively.
Sullivan Keith J reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that President and CEO Keith J. Sullivan received a grant of 112,500 shares of common stock. The shares were issued for no cash consideration upon satisfaction of performance criteria tied to performance-based restricted stock units. Following this award, Sullivan directly holds 1,637,213 shares of Neuronetics common stock. This is a compensation-related equity award rather than an open-market purchase.
Neuronetics, Inc. reported that its EVP, CLO and CS, William Andrew Macan, received an award of 33,750 shares of common stock. These shares were granted for no cash consideration after performance criteria tied to performance-based restricted stock units were satisfied. Following this equity award, his directly held common stock position increased to 913,275 shares, highlighting a compensation-related, non-market acquisition rather than an open-market purchase.
Pfanstiel Steven reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel received an equity grant of 25,000 restricted stock units (RSUs). Each RSU represents a right to receive one share of common stock, vesting in three equal annual installments beginning on March 17, 2027, subject to his continuous service. Following this award, Pfanstiel is shown as holding 845,212 shares of common stock directly.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 531,000 shares of common stock at a weighted average price of $1.16 per share. The filing notes the shares were bought in multiple trades between $0.91 and $1.31 per share. Following this transaction, Chernett directly owns 7,516,404 shares of Neuronetics common stock.
Neuronetics, Inc. reported that significant shareholder Jorey Chernett beneficially owns 6,985,404 shares of the company’s common stock. This Form 3 filing is an initial statement of holdings by a more than ten percent owner and does not reflect any new share transactions.
Neuronetics, Inc. filing amends beneficial ownership disclosure for Jorey Chernett. As of the close of business on March 17, 2026, the Reporting Person beneficially owned 7,516,404 shares of Common Stock, representing 10.85% of the class based on 69,276,593 Shares outstanding as of March 10, 2026.
The amendment updates the Schedule 13G/A ownership figures and reports sole voting and dispositive power over the disclosed shares. The statement is signed and dated 03/18/2026.
Neuronetics, Inc. registers up to 20,737,061 shares of its common stock for resale by selling stockholders pursuant to a shelf prospectus dated March 17, 2026.
The prospectus states the Company will receive no proceeds from these sales and identifies Madryn-related entities as the primary selling stockholders, who beneficially owned a combined portion of outstanding shares as of March 10, 2026. The filing describes distribution methods, indemnities, and that the shares represent a significant percentage of outstanding common stock, which could affect market price if sold concurrently.
Neuronetics, Inc. ownership filing: Parian Ultreia reports beneficial ownership of 4,844,908 shares, equal to 7.0% of the class, with sole voting and dispositive power over those shares. The filing is signed by Portfolio Manager Zachary Miller on 03/17/2026.